CureVac cites 'promising' data for its investigational cancer injection

Published Nov 10 2021 at 1:26 PM GMT
  • Shares of CureVac gained 3 5% in premarket trading on Wednesday after the company shared what it called promising data for its experimental cancer shot in a Phase 1 clinical trial.
  • The injection is being tested in 58 patients with advanced cutaneous melanoma, adenoid cystic carcinoma, and certain types of squamous cell carcinoma as part of the early-stage, open-label study.
  • CureVac recently shifted the focus of its COVID-19 vaccine development program to "second-generation" COVID-19 shots.
  • Its stock is down 55.7% so far this year, while the S&P 500 is up 25.
  • 2%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.



  • Published Nov 10, 2021 1:26 PM GMT